Amrize revises prior-period financial statements after identifying immaterial misstatements

• Amrize published revised financial statements for 2025 and interim 2025–26 periods to correct prior-period misstatements found in the June 30, 2026 quarter.
• Largest correction involved understated extended-warranty deferred revenue tied to the Duro-Last, Malarkey acquisitions; $78 million at Dec. 31, 2025.
• Revisions lowered March 31, 2025 net loss to $94 million from $87 million; March 31, 2026 net loss improved to $107 million from $118 million.
• June 30, 2025 quarter net income revised to $416 million from $428 million; six-month net income revised to $322 million from $341 million.
• Dec. 31, 2025 total assets revised to $24.21 billion from $24.25 billion; total equity revised to $13.12 billion from $13.25 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amrize AG published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.